Stock of the Day

BioLineRx (BLRX)

$6.36

+$1.09 (+20.7%)

Market Cap: $21.15M

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Recent News

• 3 Stocks Getting Rare Double Upgrades From Analysts (BLRX) (marketbeat.com)
• BioLineRx upgraded to Buy from Hold at JonesResearch (finance.yahoo.com)
• Small Stocks, But Explosive: These 10 Firms Crushed The Market Last Week (insidermonkey.com)
• Jones Trading Upgrades BioLineRx - Depositary Receipt () (BLRX) (msn.com)
• BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating (msn.com)
• Why Is Nano-Cap BioLineRx Stock Surging On Friday? (benzinga.com)